Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


Karen Bartlett

  • Litigation: Post-Mensing sands still shifting on generic design defect claims

    Pharmaceutical companies anticipate that the next several months will provide needed clarity and consistency regarding the pre-emption landscape for manufacturers of generic pharmaceutical products, with the Supreme Court scheduled to hear oral argument on March 19 in Mutual Pharmaceutical Co. Inc. v. Bartlett.

  • Supreme Court takes up design-defect drug case

    The Supreme Court on Friday agreed to review an appeals court’s decision that generic drug manufacturers can face lawsuits over alleged problems in the design of drugs, regardless of federal protections against design-defect claims.

  • Roundup: 1st, 3rd, 5th and D.C. Circuits

    Design defect claims against generic drugs not preempted; Employer owns copyright of computer program worker developed at home; Texas cannot defund Planned Parenthood; Citations under OSHA subject to six-month statute of limitations

Advertisement. Closing in 15 seconds.